# BioFire Diagnostics **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** infectious disease diagnostics, multiplex PCR, syndromic testing, in vitro diagnostics, life sciences **Stage:** Established subsidiary of bioMérieux (Euronext: BIM); global deployment **Location:** Salt Lake City, UT **Updated:** 2026-06-18 **Needs-reviewed:** 2026-06-18 **Hero:** https://picsum.photos/seed/biofire-filmarray-syndromic-pcr-2026/1600/1100 **Pull:** *One small sample, dozens of pathogens, an answer in about an hour.* ## Summary BioFire Diagnostics is a Salt Lake City company that makes syndromic infectious-disease tests — single cartridges that run multiplex PCR against roughly 20 or more pathogens at once and return results in about an hour. Its FilmArray system and panel menu (respiratory, gastrointestinal, blood culture identification, meningitis/encephalitis, pneumonia, and a newer Global Fever Panel) are used widely in US hospital labs. The company's own product labeling lists BioFire Diagnostics, LLC at 515 Colorow Drive, Salt Lake City, and identifies it as part of French clinical-diagnostics group bioMérieux. [source:biofire-diagnostics-official-website] For the Great Work Utah wiki, BioFire is one of the clearest examples of globally deployed, clinically consequential medical technology that is designed and manufactured in Utah but rarely described as "tech." ## Impact Traditional infectious-disease workups are slow and serial: culture a sample, wait a day or more, then order targeted PCR if culture fails. During that window clinicians often prescribe broad-spectrum antibiotics, which fuels resistance and can miss the real pathogen. BioFire's approach collapses that into a single self-contained run. A respiratory panel can identify COVID, influenza, RSV, and a dozen other targets from one swab; a meningitis/encephalitis panel can help distinguish bacterial from viral causes in roughly an hour rather than days, which changes treatment decisions directly. The impact mechanism is direct clinical deployment at scale: every panel that correctly identifies a viral infection and avoids an unnecessary antibiotic, or that names a bloodstream pathogen earlier than culture, is a concrete contribution to patient care and to slowing antimicrobial resistance. ## What They Are Building The flagship is the FilmArray platform (FilmArray 2.0 and Torch systems) plus a growing menu of disposable test pouches. The most recent notable addition is the BioFire Global Fever Panel, an FDA-cleared in vitro diagnostic that detects six fever-causing targets — including dengue, chikungunya, *Leptospira*, and *Plasmodium* species (malaria) — directly from EDTA whole blood in about 50 minutes with roughly two minutes of hands-on time. BioFire's labeling indicates the Global Fever Panel was cleared through a De Novo pathway (DEN200043). A research-use-only version of the panel detects a broader set of targets for surveillance work. [source:biofire-diagnostics-official-website] The harder-to-see product is the manufacturing and regulatory system: building nested multiplex PCR, integrated sample extraction, and automated detection into a single consumable that a technician can run without sample prep, then clearing each new panel through FDA review. That accumulated capability is the moat. ## What They Need Now Likely needs include assay-development and molecular-biology scientists, clinical laboratory scientists, regulatory-affairs specialists with 510(k), De Novo, and CE-IVD experience, and manufacturing and quality engineers who can build diagnostic consumables at scale. Because BioFire operates as bioMérieux's molecular-diagnostics center of excellence, operators comfortable inside a structured, global corporate environment — rather than an early-stage startup — fit best. For talent matching, BioFire suits scientists and engineers who want to ship clinically deployed infectious-disease testing at real volume while staying in Utah rather than relocating to Boston or the Bay Area. ## Who Could Help Useful helpers include FDA regulatory counsel and IVD regulatory consultants, EU IVDR compliance specialists, diagnostic quality-system advisors, and manufacturing-automation experts for sterile single-use devices. As a large established employer, BioFire is more often a customer of these services than a startup seeking them, but Utah's diagnostics and life-sciences service cluster is directly relevant to its supply base and to people moving between BioFire and smaller Utah ventures. ## Utah Context BioFire is one of the larger life-sciences employers in Salt Lake City and a meaningful anchor of Utah's molecular-diagnostics workforce. Its origin is local and unusual: the company grew out of Idaho Technology, a Utah firm with roots in rapid-PCR and biothreat-detection work, was renamed BioFire, and was acquired by bioMérieux in 2014. The result is a Utah-built diagnostics capability now operating as the molecular center of excellence for a French parent — a pattern worth understanding for anyone studying how Utah deep tech scales through acquisition rather than IPO. ## Evidence - [Source: BioFire Diagnostics Official Website and Product Labeling](biofire-diagnostics-official-website.md) ## Open Questions - Current employee count, revenue contribution to bioMérieux, and the exact split of R&D versus manufacturing in Salt Lake City are not confirmed from primary sources in this pass; the often-cited ~1,500-employee figure should be verified before use in a recommendation. - The 2014 bioMérieux acquisition price (commonly reported around $450M) is from secondary coverage and was not confirmed here against a primary filing. - How much strategic and capital-allocation autonomy the Salt Lake City operation retains under bioMérieux is unclear and matters for anyone weighing mission control versus stability. - Imagery is a deterministic placeholder. A license-cleared photograph of the FilmArray system, a cartridge, or the Salt Lake City facility — approved by the company — should replace the placeholder before this renders as a marquee page.